UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy

Muscle & nerve, 2014-07, Vol.50 (1), p.40-46

2014

Volltextzugriff (PDF)

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study

Circulation (New York, N.Y.), 2019-01, Vol.139 (4), p.431-443

2019

Volltextzugriff (PDF)

Causes of neuropathy in patients referred as "idiopathic neuropathy"

Muscle & nerve, 2016-06, Vol.53 (6), p.856-861

2016

Volltextzugriff (PDF)

Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee

Muscle & nerve, 2023-10, Vol.68 (4), p.356-374

2023

Volltextzugriff (PDF)

Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy

Muscle & nerve, 2017-04, Vol.55 (4), p.476-482

2017

Volltextzugriff (PDF)

2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee

Journal of the American College of Cardiology, 2023-03, Vol.81 (11), p.1076-1126

2023

Volltextzugriff (PDF)

Post–COVID‐19 vaccine small‐fiber neuropathy and tinnitus treated with plasma exchange

Muscle & nerve, 2022-10, Vol.66 (4), p.E21-E23

2022

Volltextzugriff (PDF)

Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials

Arquivos de neuro-psiquiatria, 2024-06, Vol.82 (6), p.1-7

2024

Volltextzugriff (PDF)

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

Journal of neurology, 2020-04, Vol.267 (4), p.1070-1079

2020

Volltextzugriff (PDF)

Neuromuscular complications of hematopoietic stem cell transplantation

Muscle & nerve, 2015-10, Vol.52 (4), p.480-487

2015

Volltextzugriff (PDF)

Current treatments of chronic immune-mediated demyelinating polyneuropathies

Muscle & nerve, 2009-05, Vol.39 (5), p.563-578

Brannagan III, Thomas H.

2009

Volltextzugriff (PDF)

A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A

Orphanet journal of rare diseases, 2021-10, Vol.16 (1), p.433-433, Article 433

2021

Volltextzugriff (PDF)

Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts

Muscle & nerve, 2024-03, Vol.69 (3), p.273-287

2024

Volltextzugriff (PDF)

Liver‐directed drugs for transthyretin‐mediated amyloidosis

Journal of the peripheral nervous system, 2022-12, Vol.27 (4), p.228-237

2022

Volltextzugriff (PDF)

Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

Amyloid, 2020-07, Vol.27 (3), p.153-162

2020

Volltextzugriff (PDF)

Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Neurology, 2022-06, Vol.98 (23)

2022

Volltextzugriff (PDF)

Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy

Proceedings of the National Academy of Sciences - PNAS, 2021-01, Vol.118 (4)

2021

Volltextzugriff (PDF)

Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial

Journal of the peripheral nervous system, 2023-09, Vol.28 (3), p.436-449

2023

Volltextzugriff (PDF)

Consensus statement: The use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the aanem AD HOC committee

Muscle & nerve, 2009-11, Vol.40 (5), p.890-900

2009

Volltextzugriff (PDF)

Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease

Muscle & nerve, 2019-11, Vol.60 (5), p.528-537

2019

Volltextzugriff (PDF)

Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A

Orphanet journal of rare diseases, 2024-04, Vol.19 (1), p.142-142, Article 142

2024

Volltextzugriff (PDF)

Neurologic Safety Monitoring of COVID-19 Vaccines: Lessons From the Past to Inform the Present

Neurology, 2021-10, Vol.97 (16), p.767-775

2021

Volltextzugriff (PDF)

Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72

JAMA neurology, 2014-06, Vol.71 (6), p.771

2014

Volltextzugriff (PDF)

RAGE Deficiency Improves Postinjury Sciatic Nerve Regeneration in Type 1 Diabetic Mice

Diabetes (New York, N.Y.), 2013-03, Vol.62 (3), p.931-943

2013

Volltextzugriff (PDF)

1 – 25 von 208

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(171)
Mit Volltextzugriff
(142)

Publikationsform

Artikel
(176)
Buchkapitel
(25)
Berichte
(6)
Bücher
(1)

Sprache

Englisch
(208)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study

Causes of neuropathy in patients referred as "idiopathic neuropathy"

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee

Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy

2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee

Post–COVID‐19 vaccine small‐fiber neuropathy and tinnitus treated with plasma exchange

Anti-MAG neuropathy: historical aspects, clinical-pathological correlations, and considerations for future therapeutical trials

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

Neuromuscular complications of hematopoietic stem cell transplantation

Current treatments of chronic immune-mediated demyelinating polyneuropathies

A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A

Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts

Liver‐directed drugs for transthyretin‐mediated amyloidosis

Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis

Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy

Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial

Consensus statement: The use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the aanem AD HOC committee

Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease

Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A

Neurologic Safety Monitoring of COVID-19 Vaccines: Lessons From the Past to Inform the Present

Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72

RAGE Deficiency Improves Postinjury Sciatic Nerve Regeneration in Type 1 Diabetic Mice

Suchergebnisse filtern